Mosunetuzumab with Lenalidomide Augmentation As First-Line Therapy for Follicular (FL) and Marginal Zone Lymphoma (MZL)
Olszewski A, Huntington S, Bannerji R, Ollila T, McMahon J, Dubielecka P. Mosunetuzumab with Lenalidomide Augmentation As First-Line Therapy for Follicular (FL) and Marginal Zone Lymphoma (MZL). Blood 2022, 140: 6492-6493. DOI: 10.1182/blood-2022-157463.Peer-Reviewed Original Research